Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 19, 2010
Dow Jones reported Friday that the Food and Drug Administration warned about the increased risk of muscle injury for those taking an 80-milligram dose of Merck & Co.'s (NYSE:MRK) Zocor, generically known as Simvastatin.
Muscle injury is a known side effect for statins, but the FDA said its warning highlights increased risks for 80-milligram Zocor, in particular for a serious form of injury that can lead to severe kidney damage, kidney failure and even death.
"Review of simvastatin is part of an ongoing FDA effort to evaluate the risk of statin-associated muscle injury and to provide that information to the public as it becomes available," said FDA official Eric Colman.